Critical issues in gene therapy for neurologic disease

Human Gene Therapy

Volumn 13, Issue 5, 2002, Pages 579-604

  Hsich, Gary ^a   Sena Esteves, Miguel ^a   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASPARTOACYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVODOPA; LYSOSOME ENZYME; NERVE GROWTH FACTOR; RECOMBINANT DNA; RETROVIRUS VECTOR; SOMATOMEDIN C; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; AMPLICON; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CANAVAN DISEASE; CELL MIGRATION; CELL TRANSFER; CEREBROSPINAL FLUID; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG SAFETY; DRUG UPTAKE; GENE REPLACEMENT THERAPY; GENE TARGETING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; INJECTION; LYSOSOME STORAGE DISEASE; NERVE CELL; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEM CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

CENTRAL NERVOUS SYSTEM DISEASES; GENE THERAPY; GENETIC VECTORS; HUMANS; RISK FACTORS;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; LENTIVIRUS; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0036202298     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252837198     Document Type: Review

References (286)

1. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
2. From the cover: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas
3. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
4. Cre-mediated somatic site-specific recombination in mice
5. Transfer of a foreign gene into the brain using adenovirus vectors
6. Models of brain injury and alterations in synaptic plasticity
7. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases
8. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors
9. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M
10. The subventricular zone: Source of neuronal precursors for brain repair
11. Human gene marker/therapy clinical protocols (protocol 322)
12. Neural-targeted gene therapy for rodent and primate hemiparkinsonism
13. BCL-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia
14. Traffic jam: A compendium of human diseases that affect intracellular transport processes
15. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF
16. Gene therapeutic strategies for neurodegenerative diseases
17. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors
18. Spongy degeneration of the central nervous system in infancy
19. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease
20. Convection enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
21. Is there a rationale for neuroprotection against dopamine toxic Parkinson's disease?
22. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease
23. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes
24. Double transduction with GTP cyclohydrolase 1 and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts
25. HSP27: A sensory neuron survival factor - Use of herpes simplex virus based vectors for gene delivery in vitro andin vivo
26. Chronic systemic pesticide exposure reproduces features of Parkin-son's disease
27. Delivery of peptides and proteins through the blood-brain barrier
28. N-Acetyl-L-aspartic acid: A literature review of a compound prominent in1H-NMR spectroscopy studies of the brain
29. Convection-enhanced delivery of macromolecular in the brain
30. A new syntaxin family member implicated in targeting of intracellular transport vesicles
31. Syntaxin 6 functions in trans-Golgi network vesicle trafficking
32. Parkinson's disease: A neurodegenerative disease particularly amenable to gene therapy
33. Infectious disease issues in xenotransplantati on
34. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors
35. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer
36. From marrow to brain: Expression of neuronal phenotypes in adult mice
37. p75NTR and apoptosis: Trk-dependent and Trk-independent effects
38. Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo
39. Enzyme replacement therapy in mucopolysaccharidosis VI: Evidence for immune responses and altered efficacy of treatment in animal models
40. Adenovirus gene transfer causes inflammation in the brain
41. The potential of extrachromosomal replicating vectors for gene therapy
42. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
43. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
44. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver
45. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus insertion mutants
46. Retrovirus therapy of tumors with activated Ras pathway
47. The herpes simplex virus 2 kb latency associated transcript (LAT) leader sequence allows efficient expression of downstream proteins which is enhanced in neuronal cells: Possible function of LAT ORFs
48. Kinetic stabilization of thea-synuclein protofibril by a dopamine-α-synuclein adduct
49. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors
50. Gene therapy in the CNS
51. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome
52. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma
53. Gene therapy for the treatment of malignant brain tumors with in vivo tumor trans-duction with the herpes simplex thymidine kinase gene/ganciclovir system
54. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
55. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged b-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice
56. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
57. Gene therapy for oxidant injury-related diseases: Adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury
58. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector
59. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
60. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts
61. Gene therapy and retinitis pigmentosa: Advances and future challenges
62. Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
63. N-Acetylaspartic aciduria: Report of three new cases in children with a neurological syndrome associating microcephaly and leukodystrophy
64. Structural and functional heterogeneity of integrated recombinant AAV genomes
65. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
66. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation
67. Ubiquinone (coenzyme Q10) and mito-chondrial in oxidative stress of Parkinson's disease
68. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: A phase I trial
69. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): A phase I trial
70. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector
71. Controversies in the therapy of Parkinson's disease
72. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain
73. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
74. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX
75. Gene transfer to neurons using herpes simplex virus-based vectors
76. Design and application of HSV vectors for neuroprotection
77. Defective herpes simplex virus vectors expressing the rat brain stress-inducible heat shock protein 72 protect cultured neurons from severe heat shock
78. Harvesting the neural gene therapy fruit
79. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells
80. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease
81. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
82. Properties of PC12 pheochromocytoma cells transplanted to the adult rat brain
83. Transplantation of B16/C3 melanoma cells into the brains of rats and mice
84. Minireview: The herpes simplex virus amplicon - A versatile defective virus vector
85. The evolution of public review and oversight mechanisms in human gene transfer research: Joint roles of the FDA and NIH
86. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF
87. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat
88. Mammalian neural stem cells
89. In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin, and lipids in Lewy bodies
90. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene
91. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo
92. Extensive β-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain
93. BDNF and NT-3, but not NGF, prevent axotomy-induced death of rat corticospinal neurons in vivo
94. Potential salmon sperm origin of the E3 region insert of the adenovirus 5dl309 mutant
95. Intergeneric poliovirus recombinants for the treatment of malignant glioma
96. Widespread gene transfection into the central nervous system of primates
97. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin
98. Methods for gene delivery to neural tissue
99. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study
100. The importance of gene dosage studies: Mutational analysis of the parkin gene in early-onset parkinsonism
101. Intra-ocular gene therapy for lysosomal storage disease using an AAV vector
102. The transcription factor Sp1 binds to the JC virus promoter and is selectively expressed in glial cells in human brain
103. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
104. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): Long-term follow-up
105. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase
106. The interaction of phosphorylated oligosaccharides and lysosomal enzymes with bovine liver cation-dependent mannose 6-phosphate receptor
107. Allogeneic bone marrow transplantation for lysosomal storage diseases
108. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype
109. Exogenous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: Grafting in an animal model of Parkinson's disease
110. Bradykinin selectively opens blood tumor barrier in experimental brain tumors
111. Over-expression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion
112. Parkinson's disease: Interpretations of transplantation study are erroneous
113. Sleeping Beauty, a wide host-range transposon vector for gene transformation in vertebrates
114. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity
115. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin
116. Transport of surface mannose 6-phosphate receptor to the Golgi complex in cultured human cells
117. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells
118. Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury
119. Characteristics of glial reaction in the perinatal rat cortex: Effect of lesion size in the "critical period"
120. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
121. Purification, characterization, and localization of aspartoacylase from bovine brain
122. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors
123. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
124. Progress in the clinical and molecular genetics of familial parkinsonism
125. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
126. Characterization of astroglial cell proliferation in vitro and in vivo
127. Engraftment of genetically engineered amniotic epithelial cells corrects lysosomal storage in multiple areas of the brain in mucopolysaccharidosis type VII mice
128. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications
129. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
130. Pathogenesis and pathology of focal malformations of cortical development and epilepsy
131. N-Acetylaspartic aciduria in a child with a progressive cerebral atrophy
132. Expression of human β-hexosaminidase α-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells
133. Neurotrophic factors and gene therapy in spinal cord injury
134. Hybrid vector designs to control the delivery, fate and expression of transgenes
135. Potential of gene therapy for brain tumors
136. Bone marrow transplantation in metachromatic leukodystrophy caused by saposin-B deficiency: A case report with a 3-year follow-up period
137. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector
138. Mannose 6-phosphate receptors regulate the formation of clathrin-coated vesicles in the TGN
139. Mannose 6-phosphate receptors and ADP-ribosylation factors cooperate for high affinity interaction of the AP-1 Golgi assembly proteins with membranes
140. Differential neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions
141. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via co-expression of GTP cyclohydrolase I with tyrosine hydroxylase
142. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease
143. Aspartoacy-lase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease
144. Gene therapy of Canavan disease using AAV vectors: A phase I clinical trial
145. Nerve growth factor
146. Neuronal molecular mimicry in immune-mediated neurologic disease
147. Integration adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes
148. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo
149. Transplantation of fetal dopamine neurons in Parkinson's disease: One year of clinical and neurophysiological observations in patients with putaminal implants
150. Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression
151. Long-term promoter activity during herpes simplex virus latency
152. Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates
153. Genetic engineering within the adult brain: Implications for molecular approaches to behavioral neuroscience
154. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: In vitro characterization and in vivo effects in the rat Parkinson model
155. Direct delivery of leptin to the hypothalamus using recombinant adeno-associated virus vectors results in increased therapeutic efficacy
156. Neural stem cells as engraftable packaging lines can mediate gene delivery to microglia: Evidence from studying retroviral env-related neurodegeneration
157. Characterization of intrastriatal recombination adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease
158. Intrabodies as antiviral agents
159. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells
160. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
161. Problems with long-term levodopa therapy for Parkinson's disease
162. A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse
163. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease
164. Knock-out mouse for Canavan disease: A model for gene transfer to the central nervous system
165. Gene therapy for autoimmune demyelinating disease of the central nervous system
166. Aging and extrapyramidal function
167. Stem cells - Hype and hope
168. Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat
169. mu1A-adaptin-deficient mice: Lethality, loss of AP-1 binding and rerouting of mannose 6-phosphate receptors
170. Adeno-associated virus vectors for gene therapy: More pros than cons?
171. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
172. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts
173. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts
174. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs
175. Transplantation of adult derived myoblasts in mice following gene transfer
176. Tyrosine hydroxylase
177. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease
178. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
179. Lysosomal storage diseases
180. Inborn errors of mucopolysaccharide metabolism
181. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption
182. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration
183. Adenovirus-mediated gene transfer and expression of human β-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice
184. Gene therapy of malignant gliomas: A phase I study of IL-4-HSV-TK gene modified autologous tumor to elicit an immune response
185. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
186. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
187. The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells
188. Is there a mechanism for introducing acid hydrolases into liver lysosomes that is independent of mannose 6-phosphate recognition? Evidence from I-cell disease
189. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration
190. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method
191. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector
192. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse
193. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome
194. Limitations in the neuroprotective potential of gene therapy with Bcl-2
195. Gene therapy effectiveness differs for neuronal survival and behavioral performance
196. Delayed recovery of movement-related cortical function in Parkinson's after striatal dopaminergic grafts
197. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases
198. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin
199. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin
200. Mutation in the αsynuclein gene identified in families with Parkinson's disease
201. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system
202. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
203. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms
204. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
205. Application of ex vivo gene therapy in the treatment of Parkinson's disease
206. Site-specific integration mediated by a hybrid adenovirus-adeno /associated virus
207. Region-specific differentiation of the hippocampal stem cell line HiB5 upon implantation into the developing mammalian brain
208. Gene transfer techniques for the delivery of GDNF in Parkinson's disease
209. Mannose-6-phosphate-independent targeting of cathepsin D to lysosomes in HepG2 cells
210. Molecular basis of lysosomal enzyme recognition: Three-dimensional structure of the cation-dependent mannose 6-phosphate receptor
211. Grafting genetically modified cells to the damaged brain: Restorative effects of NGF expression
212. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
213. Herpes simplex virus-enhanced cationic lipid/DNA-mediated transfection
214. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
215. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms
216. Three forms of dominant amyloid neuropathy
217. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome
218. Inflammatory mediators and neonatal brain damage
219. In vivo delivery of human α-L-iduronidase in mice implanted with neo-organs
220. Detection of Herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction
221. Enzyme replacement therapy for murine mucopolysaccharidosis type VII
222. Transthyretin amyloidosis: A tale of weak interactions
223. Ependymal reactions to injury. A review
224. Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
225. Immunosuppressive therapies for the twenty-first century
226. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors
227. Gene delivery to the nervous system using retroviral vectors
228. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons
229. HSV-1 amplicon vectors - Simplicity and versatility
230. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse
231. Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements
232. Triple transduction with adeno-associated virus vectors expression tyrosine aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease
233. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases
234. Noninvasive gene targeting to the brain
235. Transplanted neuroblasts differentiate appropriately into projection neurons with correct neurotransmitter and receptor phenotype in neocortex undergoing targeted projection neuron degeneration
236. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line
237. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease
238. Enzyme replacement in a canine model of Hurler syndrome
239. Sustained production of β-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice
240. Oncolytic viruses as novel anticancer agents: Turning one scourge against another
241. Multipotent neural cell lines can engraft and participate in development of mouse cerebellum
242. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain
243. Gene therapy: Trials and tribulations
244. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease
245. Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression
246. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice
247. Multiple C-terminal motifs of the 46-kDa mannose 6-phosphate receptor tail contribute to efficient binding of medium chains of AP-2 and AP-3
248. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
249. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity
250. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease
251. The problems of delivering neuroactive molecules to the CNS
252. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glu-curonidase
253. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases
254. Kinesin and cytoplasmic dynein in spinal spheroids with motor neuron disease
255. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors
256. Selective degeneration of Purkinje cells with Lewy body-like inclusions in aged NFHLACZ transgenic mice
257. New strategies in neural repair
258. Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: Implications for gene therapy of X-linked adrenoleukodystrophy
259. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36
260. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease
261. An infectious transfer and expression system for genomic DNA loci in human and mouse cells
262. Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector
263. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease
264. A hybrid herpes virus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo
265. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus
266. Recent advances in retrovirus vector-mediated gene therapy: Teaching an old vector new tricks
267. Mechanism of prion loss after Hsp104 inactivation in yeast
268. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA
269. Herpesvirus vector gene transfer and expression of b-glucuronidase in the central nervous system of MPS VII mice
270. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer
271. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors
272. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22
273. Recombinant human adenovirus: Targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium
274. Elevation of neuronal expression of NAIP reduced ischemic damage in the rat hippocampus
275. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
276. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells
277. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury
278. Towards global and long-term neurological gene therapy: Unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS
279. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection
280. Significantly increased expression of β-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector
281. Dopamine induces apoptosis like cell death in cultured sympathetic neurons - A possible novel pathogenetic mechanism in Parkinson's disease
282. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease
283. Treatment of Parkinson's disease. Symptomatic cell therapies: Cells as biological minipumps
284. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells